AA
ITOS

ALPS Advisors’s iTeos Therapeutics ITOS Stock Holding History

ALPS Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,653
Closed -$206K – 1094
2025
Q2 		$206K Sell
20,653
-7,993
-28% -$64.4K ﹤0.01% 1005
2025
Q1 		$171K Sell
28,646
-894
-3% -$6.56K ﹤0.01% 968
2024
Q4 		$227K Buy
29,540
+3,065
+12% +$26.3K ﹤0.01% 964
2024
Q3 		$270K Sell
26,475
-1,719
-6% -$26.2K ﹤0.01% 968
2024
Q2 		$418K Buy
28,194
+2,910
+12% +$41.7K ﹤0.01% 621
2024
Q1 		$345K Buy
25,284
+88
+0.3% +$959 ﹤0.01% 855
2023
Q4 		$276K Sell
25,196
-1,230
-5% -$12.2K ﹤0.01% 894
2023
Q3 		$289K Buy
26,426
+137
+0.5% +$1.75K ﹤0.01% 894
2023
Q2 		$348K Buy
26,289
+2,854
+12% +$40.7K ﹤0.01% 737
2023
Q1 		$319K Sell
23,435
-16,262
-41% -$291K ﹤0.01% 810
2022
Q4 		$775K Buy
39,697
+4,652
+13% +$90.9K 0.01% 524
2022
Q3 		$668K Buy
35,045
+13,965
+66% +$322K 0.01% 548
2022
Q2 		$434K Buy
+21,080
New +$500K ﹤0.01% 634

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ALPS Advisors's ITOS Position: Q3 2025 in Review

ALPS Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 20,653 shares — an estimated $206K sold.

ALPS Advisors first reported a position in ITOS in Q2 2022 and held it in 13 quarters. The position peaked at $775K in Q4 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • ALPS Advisors reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ALPS Advisors sold 20,653 iTeos Therapeutics shares in Q3 2025, an estimated $206K.
  • ALPS Advisors first reported a position in iTeos Therapeutics in Q2 2022 and held it in 13 quarters.
  • ALPS Advisors's iTeos Therapeutics position peaked at $775K in Q4 2022.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on ALPS Advisors's 13F filing for Q3 2025, filed 5 Nov 2025.